<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727387</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/AIEOP EW-2</org_study_id>
    <nct_id>NCT02727387</nct_id>
  </id_info>
  <brief_title>Protocol for the Treatment of Metastatic Ewing Sarcoma</brief_title>
  <acronym>EW-2</acronym>
  <official_title>Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy,
      radiotherapy and maintenance therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study for the treatment of Ewing metastatic sarcoma with and induction phase with Vincristine
      (VIN), Adriamycin (ADM), Ciclofosfamide(CYC), Ifosfamide(IFO), Etoposide(ETO) and
      radiotherapy (RT)followed by a consolidation phase with Busulfan and Melfalan (BUMEL) and
      Peripheral Blood Stem Cells Transplantation (PBSCT) and a subsequent maintenance phase with
      Ciclofosfamide and Celecoxib for High Risk (HR) patients.

      Very High Risk (VHR) patients will receive a prior frontline therapy with Temozolomide and
      Irinotecan (TEMIRI), while patient with lung metastasis only will undergo to total lung
      irradiation after PBSCT
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2009</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Expected average 3 year</time_frame>
    <description>Evaluation of the OS in patients treated according to the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (DFS)</measure>
    <time_frame>Expected average 1 year</time_frame>
    <description>Evaluation of the time in which the patient do not experience any progression, relapse of toxicity event when treated according to the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Incidence and grade of treatment-emergent Adverse Events</measure>
    <time_frame>every 21 days up to 1 year</time_frame>
    <description>Incidence and grade of treatment-emergent Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of life using Pediatric Quality of Life Inventory (PedQL) -in child and adolescents(EORTC QLQ-C30) for children and adolescents</measure>
    <time_frame>every 3 weeks for the first 6 months and 3 monthly up to 1 year</time_frame>
    <description>Evaluation of patient's Quality of life: comparison of the Baseline and On treatrment quality of life score using PedQL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of life using European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients (EORTC QLQ-C30) for adult patients</measure>
    <time_frame>every 3 weeks for the first 6 months and 3 monthly up to 1 year</time_frame>
    <description>Evaluation of patient's Quality of life: comparison of the Baseline and On treatrment quality of life score using EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Ewing's Sarcoma (ES)</condition>
  <arm_group>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2cycles of Temozolomide(500 mg/m2)+Irinotecan(250 mg/m2) and 2cycles of Vincristine(1.4mg/m2)+ Adriamycin(90mg/m2)+Ifosfamide (9gr/m2) alternes with 2 cycles of Ciclofosfamide(4g/m2)+Etoposide (600mg/m2) followed by radiotherapy (42-54 Gy) and 2cycles of Ifosfamide (9gr/m2) + Etoposide(300mg/m2) alternes with to 2cycles of Vincristine (1.4mg/m2)+ Adriamycin (80mg/m2)+ Ciclofosfamide(1.2g/m2) and Busulfan(0.8-1.2 mg/Kg)+Melfalan(140 mg/m2)+PBSCT and 6 months with Celecoxib (500mg/m2/die for&lt;14 years old ,800 mg/die for&gt;14 years old) Ciclofosfamide (oral therapy 35mg/m2/die for&lt;14 years old, 50 mg/m2 for&gt;14 years old)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEMIRI</intervention_name>
    <description>Window therapy frontline for VHR patients</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Temozolomide + Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADM</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFO</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Ifosfamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETO</intervention_name>
    <description>Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Etoposide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BUMEL</intervention_name>
    <description>Consolidation phase</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>busulfan + melphalan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VIN</intervention_name>
    <description>Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide</description>
    <arm_group_label>TEMIRI+VIN+ADM+IFO+ CYC+ETO+BUMEL</arm_group_label>
    <other_name>Vincristine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven Ewing's sarcoma

          -  Age ≤ 40 years

          -  No previous treatment

          -  Multiple skeletal metastasis or bone marrow infiltration , with/without lung/pleural
             metastasis

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Localized Ewing's sarcoma

          -  Any contraindications to the study treatment

          -  Female patients who not accept to use an effective birth control method.

          -  Pregnant or breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Luksch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliero universitaria consorziale policlinico - bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servizio di Oncoematologi Pediatrica Ospedale microcitemico ASL 8</name>
      <address>
        <city>Cagliari</city>
        <zip>Rosamaria</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS materno infantile Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.italiansarcomagroup.org/wp-content/uploads/2014/04/EW2.pdf</url>
    <description>Study synopsis</description>
  </link>
  <reference>
    <citation>Picci P, Böhling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Ruggieri P, Manfrini M, Ferraro A, Casadei R, Benassi MS, Mancini AF, Rosito P, Cazzola A, Barbieri E, Tienghi A, Brach del Prever A, Comandone A, Bacchini P, Bertoni F. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997 Apr;15(4):1553-9.</citation>
    <PMID>9193352</PMID>
  </reference>
  <reference>
    <citation>Gardner SL, Carreras J, Boudreau C, Camitta BM, Adams RH, Chen AR, Davies SM, Edwards JR, Grovas AC, Hale GA, Lazarus HM, Arora M, Stiff PJ, Eapen M. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant. 2008 May;41(10):867-72. doi: 10.1038/bmt.2008.2. Epub 2008 Feb 4.</citation>
    <PMID>18246113</PMID>
  </reference>
  <reference>
    <citation>Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, Fröhlich B, Winkelmann W, Zoubek A, Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998 Mar;9(3):275-81.</citation>
    <PMID>9602261</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

